| Literature DB >> 24453812 |
Mahbubeh Bozorgi1, Zahra Memariani1, Masumeh Mobli1, Mohammad Hossein Salehi Surmaghi2, Mohammad Reza Shams-Ardekani2, Roja Rahimi1.
Abstract
Pistacia, a genus of flowering plants from the family Anacardiaceae, contains about twenty species, among them five are more popular including P. vera, P. atlantica, P. terebinthus, P. khinjuk, and P. lentiscus. Different parts of these species have been used in traditional medicine for various purposes like tonic, aphrodisiac, antiseptic, antihypertensive and management of dental, gastrointestinal, liver, urinary tract, and respiratory tract disorders. Scientific findings also revealed the wide pharmacological activities from various parts of these species, such as antioxidant, antimicrobial, antiviral, anticholinesterase, anti-inflammatory, antinociceptive, antidiabetic, antitumor, antihyperlipidemic, antiatherosclerotic, and hepatoprotective activities and also their beneficial effects in gastrointestinal disorders. Various types of phytochemical constituents like terpenoids, phenolic compounds, fatty acids, and sterols have also been isolated and identified from different parts of Pistacia species. The present review summarizes comprehensive information concerning ethnomedicinal uses, phytochemistry, and pharmacological activities of the five mentioned Pistacia species.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24453812 PMCID: PMC3876903 DOI: 10.1155/2013/219815
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Ethnomedicinal uses of selected Pistacia species.
| Species | Regions | Plant part(s) used | Traditional uses and ethnobotanical reports | Reference(s) |
|---|---|---|---|---|
|
| Algeria | Leaf | Appetizer and astringent | [ |
| Greece | Resin | Stomach ache, dyspepsia, stomach ulcer, | [ | |
| Aerial part | Stimulant, diuretic, hypertension, kidney stones, jaundice, cough, sore throat, eczema, and stomach ache | [ | ||
| Iraq | Resin | Abdominal pain | [ | |
| Iran | Resin | Gum tissue strengthener, breath deodorizer, brain and liver tonic, and gastrointestinal ailments | [ | |
| Italy | Leaf | Toothache, mycosis, herpes, abdominal and intestinal pain, rheumatism, antiseptic, cicatrizant, emollient, expectorant, and astringent | [ | |
| Jordan | Leaf | Jaundice |
[ | |
| Resin | Heart burn and stomach ache | |||
| Morocco | Leaf | Digestive disease, evil eye | [ | |
| Portugal | Leaf, bark | Gastric analgesic | [ | |
| Root | Antiseptic and antiodontalgic | [ | ||
| Seeds | Antirheumatic | [ | ||
| Stem | Buccal antiseptic | [ | ||
| Spain | Aerial part | Hypertension | [ | |
| Fruit | Influenza | [ | ||
| Leaf | Dermatophytosis in cows | [ | ||
| Tender bud | Warts | [ | ||
| Tunisia | Fruit | Edible usage, condiment, scabies, | [ | |
| Turkey | leaf | Eczema, diarrhea, throat infections, paralysis, kidney stones, Jaundice, asthma, stomach ache, astringent, anti-inflammatory, antipyretic, and stimulant | [ | |
|
| ||||
|
| Algeria | Fruit | Stomach ache, cough, stress, tonic, and | [ |
| Greek | Fruit | Mouth flavouring, tanning, and as fodder | [ | |
| Iran | Aerial part | Veterinary | [ | |
| Fruit | Antidiarrheal | [ | ||
| Resin | Peptic ulcer, mouth freshener, antiseptic, gum tissue strengthener, as chewing gum, appetizer, phlegm dissolver, astringent, laxative, demulcent, diuretic, emmenagogue, carminative, visceral inflammation, scabies, stomach, liver and kidneys tonic, gastrointestinal disorders, and motion sickness | [ | ||
| Resin, bark | Joint pains, toothache, wound healing | [ | ||
| Jordan | Fruit | Stomach ache | [ | |
| leaf | Antidiabetic | [ | ||
| Morocco | Leaf | Eye infection | [ | |
| Resin | Gum tissue strengthener, breath deodorizer, cough, chill, and stomach disease | [ | ||
| Turkey | Fruit | Mouth disease | [ | |
| leaf | As vegetables and food | [ | ||
| Resin | Wound healing | [ | ||
|
| ||||
|
| Greece | Resin | Antidote, aphrodisiac, expectorant, and treatment of leprosy | [ |
| Iran | Resin | Smoke of it as air purifier and antiseptic | [ | |
| Leaf, bark | Astringent and antidiarrhea | [ | ||
| Jordan | Resin | Diuretic, laxative, stimulant, and aphrodisiac | [ | |
| Leaf | Diuretic, antihypertensive, and treatment of jaundice | [ | ||
| Spain | Aerial part | Hypotensive and cephalalgic | [ | |
| Branch | Antiseptic | [ | ||
| Flower, leaf | Odontalgia and Dislocated joint | [ | ||
| Fruit | Antiprostatitis | [ | ||
| Turkey | Fruit | Cold, flu, diuretic, stomach ache, rheumatism, stimulant, antitussive, appetizer, as coffee, urinary inflammations, and | [ | |
| Leaf | Stomach ache, mycosis, and antidiabetic | [ | ||
| Resin | Urinary and respiratory antiseptic, asthma, antipyretic, and anti-inflammatory | [ | ||
|
| ||||
|
| Iran | Nut shell | Tonic, sedative, and antidiarrhea | [ |
| Fruit | Food | [ | ||
| Jordan | Oil | Facial skin cleanser | [ | |
| Turkey | Resin | Asthma, stomach ache, and hemorrhoids | [ | |
|
| ||||
|
| Iran | Aerial part | Veterinary use | [ |
| Resin | Stomach discomfort, nausea, vomiting, and motion sickness | [ | ||
Chemical compounds isolated from selected Pistacia species.
|
|
Pharmacological activities of selected Pistacia species.
| Pharmacological activity | Plant | Plant part | Assay | Extract/essential oil/isolated component | Dose or | Observations | Ref. |
|---|---|---|---|---|---|---|---|
| Antioxidant |
|
| In vitro DPPH method |
Polyphenols: | 1, 3, 10, 30, and | Dose dependent radical scavenging activity of GA (IC50: 2 |
[ |
| Xanthine oxidase inhibition | 100, 200, and 300 | ↑formation of uric acid and superoxide anions (O2-) by increasing concentrations of both GA and PGA | |||||
| Inhibition of lipid peroxidation induced by H2O2 in K562 cell line | 200, 400, and 800 | Dose dependent inhibition by GA (IC50: 220 | |||||
|
| Reducing power |
Seven different extracts | 100 | Higher activity of aqueous fractions from hexane and chloroform than standards (BHA and |
| ||
| Linoleic acid peroxidation | 100 | Inhibition of linoleic acid peroxidation by aqueous extracts from chloroform and hexane comparable to those of the standard (BHA) | |||||
| DPPH method | 10–100 | High scavenging activity (90%) equivalent to that of the standard BHA (89%) by all extracts except chloroform | |||||
| Scavenging activity against hydrogen peroxide | 100 | High scavenging capacity against H2O2 comparable to standards ( | |||||
|
| DPPH method | Essential oil | 0.2, 0.4, 1.0, 2.0, and 4.0 mM | Antioxidant activity ranged between 0.52 and 4.61 mmol/L | [ | ||
| DPPH method | Methanolic | 100, 80, 50, 30, 20, 10, and 5 mg/L | IC50 ranged between 5.09 and 11.0 mg/L |
| |||
| FRAP assay | 5000 mg/L | Activity ranged between 84.6 and 131.4 mmol Fe2+/L plant extract; IC50: 5.09–11.0 (mg/L) | |||||
|
| Resin | Oil oxidation assay by the oven test | Resin solution in dichloromethane | 0.05, 0.1, and 0.15% w/w | Significant antioxidant activity | [ | |
|
| Fruit | ABTS | Digallic acid | 0.05, 0.1, 0.15, and 0.2 mg/mL | Free radical scavenging activity towards the ABTS + radical was 99% at 0.2 mg/mL |
| |
| Xanthine oxidase (XO) inhibition and superoxide scavenging activity | 50, 100, and 150 | 21% XO inhibitory activity at 150 | |||||
| TBARs | 200, 400, and 800 | ↓lipid peroxidation (IC50: 178 | |||||
| Gum | Electron-spin resonance Spectroscopy for the determination of hydroxyl radical by Fenton reaction | Mastic in water | ND | Effectively scavenged hydroxyl radical generated by the |
[ | ||
| Nitrate/nitrite | 0–3 mg/mL | No nitric oxide scavenging activity | |||||
|
| Gum | Copper-induced LDL oxidation | Hexane and methanol/water extracts | 2.5, 5, 10, 25, and 50 mg/2 mL | LDL protective activity; | [ | |
|
| Leaf | Reduction power activity | Ethanolic extract | 0.25; 0.5; 0.75; | Reducing power comparable to ascorbic acid |
[ | |
| Pyrogallol autoxidation method | ND | Superoxide anions scavenging activity | |||||
|
| Leaf | Reduction power activity | Ethanolic extracts | 0.25; 0.5; 0.75; | Reducing power close to values observed by ascorbic acid |
[ | |
| Pyrogallol autoxidation method | ND | Superoxide anions scavenger at a concentration as low as 0.0625 mg/mL | |||||
|
| Hull | FRAP test | The unsaponifiable matter (USM) of fruit's hull oil | 100 mg in 10 mL of | Significant reducing power; the highest reducing power amongst the USM fractions belonged to the tocopherols and tocotrienols and linear and triterpenic alcohols respectively |
[ | |
| DPPH radical-scavenging assay | ND | EC50 value significantly lower than | |||||
| Oven test | ND | Significant stabilizing effect | |||||
|
| Leaf | (1) Reducing power | Decoction | (1) 20–100 |
(1) Reducing power of significantly higher than | [ | |
|
| Fruit hull | Rancimat |
| Different percentages (up to 15%) | The antioxidant activity of hull oil was exactly the same as that of TBHQ at low concentrations | [ | |
|
| Leaf | DPPH test | Essential oil | 50 | Weak radical scavenging activity | [ | |
| FRAP test | ND | Higher antioxidant capacity relative to ascorbic acid | |||||
|
| Fruit hull | Oven test | Water and methanol extracts | 0.02%, 0.04%, and 0.06% in soybean oil | Effective in retarding oil deterioration at 60°C; at concentration of 0.06%, similar to BHA and BHT added at 0.02%. | [ | |
|
| Kernel | ABTS radical cation decolorization assay | Methanol/water or | ND | The antioxidant activity of the lipophilic extract was much lower than hydrophilic one |
| |
| Lipid peroxidation | Hydrophilic extract | 0.25, 0.5, or 1.0 mg/mL | Radical scavenging activity in a dose-dependent manner | ||||
| Copper-mediated LDL oxidation | Hydrophilic extract | Extracts from 30, 60, or 100 | Inhibition of LDL oxidation | ||||
| Seed and skin (hull) | DPPH assay | Methanol/water extract | 0.050–12.00 mg/mL | Radical scavenging activity |
| ||
| Trolox equivalent antioxidant capacity (TEAC) assay | ND | Antioxidant power: 0.015 ± 0.001 and 2.19 ± 0.14 mmol Trolox/g of seeds and skins, respectively | |||||
| Scavenging activity against the superoxide anion | ND | IC50 of 3.25 ± 0.19 and 0.25 ± 0.02 mg for seeds and skins, respectively | |||||
|
| Gum | TBARS and FRAP in rat | Extract | 0.1–0.5 g/kg | ↓brain MDA level by 63% and ↑antioxidant power of brain by 235% |
[ | |
| Hull | DPPH assay | Aqueous | 1, 1.5, 2,5, 3,5 and 4 | Concentration-dependent radical scavenging activity |
[ | ||
| ABTS assay | ND | Scavenging capacity of crude and purified extracts was higher than standards compounds (TBHQ and BHT) | |||||
|
| 0.48–9.5 | Concentration-dependent antioxidant capacity | |||||
|
| Leaf | Trolox equivalent antioxidant capacity assay (ABTS/K2S8O2 method) | Ethanol-water extract | ND | Considerably higher antioxidant activity compared with BHA and ascorbic acid |
[ | |
| Fruits | DPPH test | Acetone and methanol extracts | 25, 50 and 100 | High radical scavenging activity |
[ | ||
| Total antioxidant activity in | 25, 50 and 100 | Isolated pure 60-hydroxyhypolaetin-30-methyl | |||||
| Superoxide anion scavenging activity | 50 | Both extracts had scavenging activity near to ascorbic acid; higher activity of methanol extract than acetone extract | |||||
| FRAP | 0.2–1 | Higher reducing power of methanol extract than | |||||
| Metal chelating activity | 1000–4000 | Methanol extract had higher activity than acetone extract | |||||
| Fruits and 4 terebinth coffee brands | DPPH radical scavenging activity | Ethyl acetate and methanol extracts | 250, 500, 1000 and 2000 |
High scavenging effect especially at 2000 |
[ | ||
| DMPD radical scavenging activity | Scavenging effect lower than that of quercetin | ||||||
| H2O2 radical scavenging activity | Inactive in scavenging H2O2 radical | ||||||
| Metal-chelation effect | Remarkable metal-chelation properties as compared to | ||||||
| FRAP assay | High reducing power | ||||||
| PRAP assay | High reducing power | ||||||
|
| |||||||
| Antimutagenic |
| Leaf | Aflatoxin B1 (AFB1)-induced mutagenicity in | Essential oil | 250, 500 and 1000 | Mutagenic inhibition of 76.7% by 250, 82.8% by 500, and 96.5% by 1000 | [ |
| (AFB1)-induced mutagenicity in | Essential oil | 0.3, 250, 500, 1000 | In TA100: 76, 82.8, and 96.5%, mutagenic inhibition rate for 250, 500, and 1000 |
[ | |||
| Aqueous extract | 0.3, 50, 300, 600 | 50 | |||||
| Flavonoid-enriched extract extracts | 50, 300, 600 | TA100: 47, 75.3, and 88.6% inhibition by 50, 300, and 600 | |||||
| Sodium azide- | Essential oil | 1.5, 10, 15, 30 | TA100: 79, 83, and 94% inhibition by 10, 15, and 30 | ||||
| Aqueous extract | 1.5, 50, 300, 600 | TA100: 92, 96, and 98% inhibition by 50, 300, and 600 | |||||
| Flavonoid-enriched extract extracts | 50, 300, 600 | 50 and 300 | |||||
|
| |||||||
| Anitmicrobial and antiviral |
|
| Disc diffusion | Essential oil | 0.03, 0.15, 0.62, 2.5, 10.0, 40.0 mg/mL | Noticeable activity against | [ |
| Disc diffusion | Ethanolic extract | 5 and 10 |
No effect on | [ | |||
| Disc diffusion | Ethanolic extract | 50, 100, 500 |
Inhibiting activity on | [ | |||
| Disc diffusion | Aqueous extract | ND |
Most active against |
| |||
| Disc diffusion | Total oligomer flavonoid-enriched extract | ND | TOF extract exhibited antibacterial activity only against | ||||
| Microdilution agar | Essential oil | ND | Activity against | ||||
|
| Gum | Disc diffusion | Essential oil and its fractions and components | ND |
| [ | |
|
| Disc diffusion | Mastic gum water (MWR) and its major constituents | MWR (58 mg/mL), (−)-trans-pinocarveol (13 mg/mL), (−)-linalool (37.6 mg/mL), (±)-linalool (36.6 mg/mL), (−)-verbenone (29.5 mg/mL), and (+)- | The broadest average inhibition zones were for |
| ||
| Microdilution | 4%, 2%, 1%, 0.5%, 0.25%, 0.125%, 0.063%, and | The most potent antimicrobial constituents were (±)-linalool and | |||||
|
| Gum | ND | Liquid mastic | 2% liquid mastic | Activity against |
| |
| Human T-cell leukemia MT-4 cells infected with HIV-1IIIB; viable cell number determination by MTT assay | Solid and liquid mastic | Solid mastic: 0–200 | Neither solid nor liquid mastic had any anti-HIV activity compared to positive controls | ||||
|
|
| Microdilution | Total mastic extract without polymer (TMEWP), | MEWP: 0.049 to 1.560 mg/mL, fractions: 0.060 to 1.920 mg/mL | The acidic fraction exhibited the highest activity against |
| |
| In vivo administration of extract in infected mice with | Total mastic extract without polymer (TMEWP) | 180 |
Moderately reduced | ||||
|
| Gum | Broth microdilution | Isolated components of the acidic fractions of the gum | ND |
The MIC values for the components ranged from 0.1 to 50 | [ | |
|
| Gum | ND | Essential oil, | ND |
Against all tested bacteria mentioned in previous row, MIC values for essential oil and pure | [ | |
|
| Leaf and twig | Modified [3H]-hypoxanthine incorporation assay | Flavone 3-methoxycarpachromene from ethyl acetate extract | 0.8 and 4.9 | IC50 of 3.4 | [ | |
| Leaf and fruit derm | Disk diffusion method | Methanol, ethanol, | 25, 50 and 75 mg/mL | Dose dependent activity against | [ | ||
|
| Disc diffusion | Ethanolic extract | 5 and 10 |
|
| ||
| Disc diffusion | Ethanolic extract | (50, 100, 500 | No inhibiting activity was observed against | ||||
| Gall | Disc diffusion | Aqueous extract | 4.9 mg |
Activity against the |
| ||
| Leaf and gall | Disc diffusion | Essential oils | Final 0.1% v/v | Delayed not block fungal growth in | |||
| Gum | Agar disc diffusion | Essential oil | 10−1, 10−2, 10−3, and 10−4
| Most active against |
[ | ||
| Inhibitory quantity (MIQ) method | 0.5, 1, 1.5, and 2 |
| |||||
| Maruzzella method | 10−1, 10−2, 10−3
|
| |||||
|
| Gum | Mice infected with | Gum | Locally rubbed on lesions |
↓Skin lesion size in mice infected with | [ | |
|
| Leaf | Microdilution | Hydroalocholic extract | 0.024, 0.049, 0.097, 0.19, 0.78, 1.56, and 25 mg/mL (for | Activity against | [ | |
| Gum | Disc diffusion, | Essential oil and gum smoke | ND | Activity of essential oil against all tested bacteria including | [ | ||
|
| Not mentiond | Disc diffusion, | Ethanolic extract and its fractions | ND | Active against Gram-positive | [ | |
| Leaf | Microdilution | Chloroform, ethyl acetate, | ND | Activity against bacteria including | [ | ||
| Leaf, fruits derm | Disc diffusion | Methanolic extract | 25, 50, 75 mg/mL |
Hydroalcoholic extract of fruits derm on | [ | ||
|
| Leaf, branch, | In vitro study on four parasitic protozoa | Lipophylic extracts | 0.8 to 9.7 | No inhibitory activity against |
| |
| Not any significant inhibitory potential against | |||||||
| Remarkable activity of branches extract at 4.8 | |||||||
| Dried leaf extract displayed notable activity against | |||||||
|
| Hole-plate, | Essential oil | 1/10, 1/20, 1/40, 1/80, |
All isolates of | [ | ||
| Agar-disc diffusion, broth microdilution, and broth susceptibility | Essential oil | of 2 and 4 |
Dose dependent activities against | [ | |||
| Hull | Disk diffusion test | Aqueous | 1200 | Gram positive bacteria were the most sensitive |
| ||
| Agar dilution method | 0.5 to 10 mg/mL | ||||||
| Leaf, branch, stem, kernel, | Microdilution | Lipophylic extracts | 256 and 512 mg/mL | Greater activity against Gram positive bacteria than Gram-negative; remarkable antifungal activity against |
| ||
| In vitro antiviral assay | Extracts of shell skin and fresh kernel had significant activity against | ||||||
|
| |||||||
|
|
|
| Phospholipase A2 (PLA2) |
| 200 mg/kg | Inhibition of edema |
|
| Ethyl phenylpropiolate (EPP) induced mouse | 1 mg/ear | Inhibition of edema by 44%. | |||||
| 12-O-Tetradecanoylphorbol-13-acetate | 1 mg/ear | Nonsignificant effect | |||||
| Mouse ear edema induced by multiple topical applications of TPA | 1 mg/ear | 58% inhibition of chronic inflammatory swelling | |||||
| In vitro phospholipase A2 activity assay | ND | ↓activity of the enzyme by 75% | |||||
| Myeloperoxidase assay | ND | ↓activity of the enzyme by 73% | |||||
| Phospholipase A2 (PLA2)-induced hind-paw mouse edema | Masticadienonic acid, masticadienolic acid, and morolic acid from methanolic extract | 30 mg/kg | Inhibition of edema by all triterpenes |
| |||
| Ethyl phenylpropiolate (EPP) induced mouse | 1 mg/ear | 31% and 38% nonsignificant inhibition of edema by masticadienolic acid and morolic acid, whereas masticadienonc acid was inactive | |||||
| Mouse ear edema induced by multiple topical | 0.3 mg/ear | Inhibition of swelling and neutrophil infiltration by all compounds | |||||
| Myeloperoxidase assay | 10–100 | 80% inhibition of enzyme activity by all the compounds | |||||
| Inhibition of the production of LTB4 from rat polymorphonuclear leukocytes (PMNL) | 12.5–100 | Inhibition of leukotriene B4 production in rat PMNL by all compounds | |||||
| Ethyl phenylpropiolate-induced mouse ear oedema | Oleanolic acid and its semisynthetic 3-oxo-analogue | 1 mg/ear | No activity on the edema |
| |||
| Mouse ear edema induced by TPA | 0.5 mg/ear | A nonsignificant 28% inhibition | |||||
| Mouse edema induced by DPP | 0.5 mg/ear | ↓swelling by 40% similar to standard (carbamazepine) | |||||
| Delayed type hypersensitivity induced by fluorobenzene | Oleanolic and oleanonic acids | 0.5 mg/ear | Oleanonic acid: ineffective at both 24 and 96 h; oleanolic acid: ↓edema nonsignificantly at 96 h by 32% | ||||
| Mouse ear inflammation induced by multiple topical applications of TPA | 0.3 mg/ear | Oleanonic acid: significant effect with 45% inhibition; oleanolic acid: inactive | |||||
| Myeloperoxidase assay | ND | Inhibition of neutrophil infiltration by oleanonic and oleanolic 84% and 67%, respectively | |||||
| Phospholipase A2-induced hind paw mouse edema | 30 mg/kg | ↓edema by both compounds | |||||
| Bradykinin-induced mouse paw edema | Oleanonic acid | 30 mg/kg | ↓edema by 61% | ||||
| Inhibition of leukotriene B4 production from rat | ND | ↓leukotriene B4 (IC50: 17 | |||||
|
| Fruits, | Carrageenan-induced hind paw edema | Ethanolic and aqueous extracts | 250, 500 mg/kg | Among all extracts, only the oleoresin exhibited a dose-dependent anti-inflammatory activity |
| |
| p-Benzoquinone-induced abdominal constriction test | 250, 500 mg/kg | Among all extracts, only the oleoresin displayed antinociceptive activity with 32.1% inhibition at 500 mg/kg and 21.7% inhibition at 250 mg/kg | |||||
|
| Hot plate test | Aqueous extract, | 0.4 and 0.5 g/Kg | Dose-dependent antinociceptive activity after 30–60 min of treatment |
| ||
| Xylene-induced ear edema | Aqueous extract | 0.4, 0.16, 0.28 g/kg | Significant anti-inflammatory activities | ||||
| Chronic anti-inflammatory activity (granuloma pouch method) | Aqueous extract, ethanolic extract | 0.4 g/Kg | Significant and dose-dependent anti-inflammatory activity | ||||
| Writhing test | Aqueous extract | 0.4, 0.28 g/kg | ↓number of mouse abdominal constrictions induced by acetic acid | ||||
|
|
| Modification of VCAM-1 and ICAM1 expression | Neutral extract and isolated | Extract: 25, 50, 100, 200 | significant dose-dependent ↓in vascular adhesion molecule 1 (VCAM-1) and intracellular adhesion molecule 1 (ICAM-1) expression |
| |
| U937 cell adhesion assay | ↓adhesion of U937 cells to TNF- | ||||||
| Measurement of NFkB p65 phosphorylation by ELISA | ↓phosphorylation of NFkB p65 | ||||||
|
| |||||||
| Effects on Gastrointestinal disorders |
| Resin | Pyloric ligation-, | Powder finely suspended in corn oil | An oral dose of 500 mg/kg | ↓intensity of gastric mucosal damage in all models | [ |
|
| Resin | TNBS-induced colitis in rats | Powder in polyherbal formulation | 50, 100, and 200 mg/kg of formula with 4% | ↓macroscopic and microscopic colonic damage; ↓TNF- | [ | |
|
| Resin | 3-week double-blind randomised placebo controlled study on patients with functional dyspepsia | Powder | 350 mg TID | Improved the feeling of symptoms significantly | [ | |
|
| Resin | Dextran-sulfate sodium (DSS) model of colitis in mice | Powder | 0.20 g/kg chow (0.02%) | Delayed the onset and progression of acute colitis and ↓weight loss caused by the disease | [ | |
|
| Resin | 4-week pilot study on 10 patients with Crohn's disease and 8 controls | Capsules of fine | 2.22 g/day (6 caps/d, 0.37 g/cap) |
↓Crohn's disease activity index and plasma inflammatory mediators such as C-reactive protein, interleukin-6 (IL-6) without any side effects; immunomodulatory effect by ↓ tumor necrosis factor-alpha (TNF- | [ | |
|
| Resin | 4-week pilot study on 10 patients with crohn's disease and 8 controls | Capsules of fine | 2.22 g/day (6 caps/d, 0.37 g/cap) | Immunomodulatory activity ↓TNF- | [ | |
|
| |||||||
|
|
| Leaf | In vitro and in vivo (normoglycemic and streptozocin-induced hyperglycemic rats) | Aqueous extract | 2 mL plant extract equivalent to 200 mg of starting material | Significant inhibitory effect on | [ |
| In vitro enzymatic starch digestion and rat model | Aqueous extract | 1, 5, 10, 12.5, 25, 50, and 100 mg/mL | In vitro: significant dose dependent dual inhibition of | [ | |||
|
| Resin | Human study | Powder diluted in 250 mL of water | 0.7 g per day |
Significantly decrease (3.1 mg/dL per month, | [ | |
|
| |||||||
|
|
| Resin | In vitro study on human colon cancer | Ethanol extract | ND | Inhibited proliferation and induced apoptosis of human colorectal tumor cells | [ |
|
|
| In vitro study on human leukemic cell line | Liquid and solid resin | 0–200 | The most cytotoxic effect against promyelocytic leukemia HL-60 among 13 human cell types; inhibition of natural apoptosis of oral polymorphonuclear leukocytes | [ | |
| In vivo human colon cancer/immunodeficient mouse model | Hexane extract | 200 mg/kg administered daily for 4 consecutive | Anticancer activity via its delay effect on the growth of colorectal tumors developed from HCT116 xenografted into mice | [ | |||
| Human cell line (androgen-responsive prostate cancer cell line) | ND | 2, 4, 6, 8, 10, and 12 | Remarkable potency to decrease the expression and function of the androgen receptor in androgen-responsive prostate cancer cell line (LNCaP) | [ | |||
| Human prostate cancer cell lines (LNCaP and DU-145), RT-PCR, and Western blotting were used to detect maspin expression | ND | 2, 4, 6, and 8 | Increased maspin expression in LNCaP cells | [ | |||
| The human prostate cancer cell lines (PC-3), MTT assay, gene assay, RT-PCR, and | ND | 10, 20, and 30 | Inhibited proliferation and blocked the cell cycle progression in androgen-independent prostate cancer PC-3 cells by suppressing NF- | [ | |||
| Lewis lung carcinoma cells | Essential oil | 0.01% v/v | A time-dependent modification in the expression of 925 genes and phenomena in Lewis lung carcinoma cells by its antiproliferative, proapoptotic, and anti-inflammatory activities | [ | |||
|
|
| Immunocompetent mice | Essential oil | 45 mg/kg intraperitoneally, 3 times a week for 3 weeks | Significant inhibition on tumor growth without signs of toxicity related to apoptosis induction, reduced neovascularization, and inhibiting chemokine expression | [ | |
| Cells line and | Essential oil | 0.01–0.1% v/v | Antiproliferative and proapoptotic effect on K562 human leukemia cells; inhibited the release of vascular endothelial growth factor from K562 and B16 mouse melanoma cell; concentration-dependent inhibition of endothelial cell proliferation without affecting cell survival; significant decrease of microvessel formation | [ | |||
| Rat liver medium-term carcinogenesis bioassay (Ito-test) | Powder in diet | 0, 0.01, 0.1 and 1% | Promoted the preneoplastic lesions development in rat liver with increasing liver relative weight | [ | |||
| human colon carcinoma HT29 cells | Ethanol : H2O (70 : 30) | 0.7 mg/mL | 50% growth inhibition similar to 500 nM of doxorubicin | [ | |||
|
| Resin | In vitro cytotoxic activity against human cell lines | Crud methanolic extract fractionated against petroleum ether, chloroform, | ND | Moderate cytotoxic effect against breast cancer cell line (MCF7), hepatocellular carcinoma cell line (HEPG2), cervix cancer cell line (HELA), and normal melanocytes (HFB4); | [ | |
|
| |||||||
| Effects on liver and serum biochemical parameters |
|
| Rat model using Carbon tetrachloride | Aqueous extract | 4 mL/kg | ↓bilirubin and activity of 3 enzymes including alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) | [ |
| Rat model using Thioacetamide | Aqueous extract | 15 mg/kg and 75 mg/kg | Hepatic fibrosis, an inflammatory response, mild cholestasis, and depletion of reduced glutathione associated with an increase in its oxidized form for five weeks administration in healthy rats; in thioacetamide-induced rat liver lesions, it aggravated the inflammatory, fibrotic, and glutathione depleting responses without affecting the extent of lipid peroxidation | [ | |||
|
| Resin | Human model | Powder diluted in one glass (250 mL) of water | 5 g | Serum total cholesterol, LDL, total cholesterol/HDL ratio, lipoprotein, apolipoprotein A-1, apolipoprotein B, AST, ALP, and gamma-GT were reduced in human subjects | [ | |
|
| Seeds oil | Rabbit model, mercury induced toxicity |
| 5% |
Mercury induced toxicity in rabbits caused increase in the level of ALP, AST, and urea serum, while it was reported that | [ | |
|
| Fruit (roasted, unsalted pistachio nuts) | Human model (10 patients with moderate hypercholesterolemia) | Nut | 20% in diet | ↓total cholesterol, total cholesterol/HDL ratio, and LDL/HDL ratio and ↑HDL after 3 weeks use | [ | |
|
| Fruit | Rabbit model | Fruit | 1 g/kg | Inhibited the development of hydropic degeneration and fatty changes in the liver and demonstrated hypolipidemic effect | [ | |
|
| |||||||
| Effects on atherosclerosis |
| Fruit | Rabbit model | Methanolic and cyclohexane extracts | Methanolic extract (1% v/w) | Beneficial effects on HDL, LDL, and aortic intimal thickness. The methanolic extract additionally showed an antioxidant activity and remarkable decrease in aortic surface lesions | [ |
|
| Fruit | Rabbit model | Fruit | 1 g/kg | Inhibited the development of the atherosclerotic lesions in the thoracic artery | [ | |
|
| Resin | Cell culture (peripheral blood mononuclear cell, PBMC); cell viability assessed via | Total polar extract | 2.7, 27, and 270 | Restored intracellular antioxidant glutathione (GSH) levels and downregulated CD36 mRNA expression resulted in antioxidant and antiatherogenic effects | [ | |
|
| |||||||
| Anticholinesterase activity |
| leaf | TLC bioautography assay, Ellman's colorimetric method | Aqueous extract | 5, 10, 15, 20, and 25 | Strong acetylcholinesterase (AChE) inhibition | [ |
|
| Leaf | Ellman's colorimetric method | Methanol and ethyl acetate extracts | 0.1 mg/mL | Relatively weak AChE inhibitory activity | [ | |
|
| Fruit | Ellman's colorimetric method and the modified dopachrome method | Ethyl acetate and methanol extracts | 25, 50, 100, and 200 | No inhibitory activity against AChE and tyrosinase while selectively inhibited butyrylcholinesterase (BChE) at moderate levels (below 50%) at the tested concentrations | [ | |